BioTel Research is in the fight against COVID-19

During the COVID-19 pandemic, BioTel Research is intensely focused on making sure you have the cardiac safety testing support you need. Our team is working tirelessly to deploy remote monitoring services that minimize person-to-person contact, while maintaining vital health information flow. We are also ensuring the continuation of current trials, as well as providing support for the rapid development of new vaccines and therapies for the novel coronaviris.

Remote cardiac monitoring has never been more important

Cardiac Monitoring Challenges During the Pandemic

  • Protections, such as social distancing and stay-at-home orders, may cause missed visits and other compliance issues

Advantages of Remote Cardiac Monitoring

  • Virtual trial capabilities — allow sponsors to reduce the number of subject visits to sites, while continuing to run studies
  • Expanded use of MCOT™ (Mobile Cardiac Outpatient Telemetry) — delivers near real-time cardiac data for subjects and sponsors in need of more immediate results
  • Home monitoring engages patients at a distance — critical to ensuring the continuous flow of high-quality data

MCOT™ (Mobile Cardiac Outpatient Telemetry)
uniquely indicated to detect QT prolongation

MCOT Used in COVID-19 Monitoring Nationwide

  • Critical component of cardiac safety testing in hospital treatment protocols and many COVID-19 trials

Cardiac Risks, Including QT Prolongation, are Associated with Some Experimental COVID-19 Therapies

  • Certain medications, including hydroxychloroquine and azithromycin, may cause QT prolongation, a condition that can lead to sudden cardiac arrest or death

MCOT: FDA-Approved to Measure, Analyze, and Report QT Intervals

  • Provides 24/7 rapid alert notification for QTc prolongation and cardiac arrhythmias
  • Once monitoring patch is applied to chest, requires minimal patient contact

The leading cardiac patch monitor for near real-time arrhythmia detection

MCOT™ Patch (Mobile Cardiac Outpatient Telemetry):
Superior Arrhythmia Detection in a Convenient, Wearable Patch

  • Near real-time monitoring and accuracy, in a simple-to-use and easy-to-wear device
  • Only cardiac monitor proven to detect atrial fibrillation (≥30 seconds) with 100% sensitivity and 100% positive predictivity*

Chosen by Professionals During the COVID-19 Pandemic — for Clinical Trials and Clinical Practice

  • Allows trial sponsors to reduce subject site visits and continue to run studies
  • Enables monitoring of patients at a distance, keeping them compliant and ensuring the flow of high-quality data
  • Only patch whose is FDA-cleared to measure, analyze, and report QT intervals

Download the MCOT Sell Sheet Now

* Based on MIT-BIH (Massachusetts Institute of Technology-Beth Israel Hospital) Atrial Fibrillation Database testing of ≥30-second AF episodes. (FDA 510k submission)

Case Study: MCOT deployed in response to COVID-19

In response to COVID-19, Northwell Health chose MCOT™ (Mobile Cardiac Outpatient Telemetry) to more closely monitor cardiac safety for patients receiving hydroxychloroquine and azithromycin.

Key Points:

  • With a limited number of telemetry beds, mobile continuous telemetry patches, which provide near real-time notification of arrhythmias, can be used to monitor inpatients in non-telemetry units
  • MCOT, in particular, can also provide serial assessments of the QT interval in patients receiving QT-prolonging medications

Download MCOT COVID-19 Case Study

Reference: 1. Gabriels J, et al. Inpatient Use of Mobile Continuous Telemetry for COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin. Heart Rhythm Case Reports. Accesed on the Web. 2 April 2020, https://www.heartrhythmcasereports.com/article/S2214-0271(20)30058-0/fulltext